Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Newsfile Corp•19/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.